16.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.09
Aprire:
$16.12
Volume 24 ore:
1.74M
Relative Volume:
0.97
Capitalizzazione di mercato:
$2.34B
Reddito:
$181.74M
Utile/perdita netta:
$-143.97M
Rapporto P/E:
-12.16
EPS:
-1.39
Flusso di cassa netto:
$9.60M
1 W Prestazione:
+7.92%
1M Prestazione:
+3.05%
6M Prestazione:
-13.99%
1 anno Prestazione:
-32.99%
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ARWR
Arrowhead Pharmaceuticals Inc
|
16.90 | 2.34B | 181.74M | -143.97M | 9.60M | -1.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-06-05 | Iniziato | Goldman | Neutral |
2023-12-04 | Iniziato | BofA Securities | Buy |
2023-09-19 | Iniziato | Citigroup | Neutral |
2023-07-21 | Iniziato | TD Cowen | Outperform |
2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
2023-04-26 | Iniziato | SMBC Nikko | Outperform |
2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
2023-03-21 | Iniziato | Bernstein | Mkt Perform |
2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2022-01-19 | Ripresa | Goldman | Buy |
2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
2021-06-04 | Ripresa | Robert W. Baird | Neutral |
2021-02-05 | Reiterato | H.C. Wainwright | Buy |
2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-12-16 | Iniziato | UBS | Buy |
2020-11-19 | Iniziato | Citigroup | Buy |
2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
2020-03-17 | Iniziato | Goldman | Neutral |
2020-01-21 | Iniziato | SVB Leerink | Underperform |
2019-12-13 | Iniziato | Oppenheimer | Perform |
2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
2019-11-27 | Reiterato | B. Riley FBR | Buy |
2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
2019-10-03 | Iniziato | Robert W. Baird | Outperform |
2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Where are the Opportunities in (ARWR) - news.stocktradersdaily.com
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail
GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans By Investing.com - Investing.com Canada
California State Teachers Retirement System Reduces Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to “Buy” at Wall Street Zen - Defense World
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey
Arrowhead at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga
Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace
Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus
(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha
Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus
Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - BioSpace
Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com
What is HC Wainwright’s Estimate for ARWR FY2025 Earnings? - Defense World
HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - Defense World
Arrowhead at RBC Conference: Strategic Insights on Drug Pipeline By Investing.com - Investing.com India
Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus
BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World
B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World
Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - Defense World
ARWR: Multiple Value Drivers for Long-Term Growth - Research Tree
Q3 Earnings Forecast for ARWR Issued By Leerink Partnrs - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum - MSN
ARWR July 18th Options Begin Trading - Nasdaq
ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance
Citigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $17.00 - Defense World
UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating - marketscreener.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings Beat - Defense World
Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus
RBC cuts Arrowhead Pharma target to $40; keeps Outperform By Investing.com - Investing.com Canada
Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus
Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus
Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR Stock News - GuruFocus
RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating - marketscreener.com
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arrowhead Pharmaceuticals Inc Azioni (ARWR) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Anzalone Christopher Richard | Chief Executive Officer |
Apr 10 '25 |
Sale |
10.87 |
50,000 |
543,500 |
3,972,055 |
Anzalone Christopher Richard | Chief Executive Officer |
Apr 09 '25 |
Sale |
10.07 |
40,322 |
406,145 |
4,022,055 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):